Iambic and Takeda Partner on AI-Driven Small Molecule Drug Discovery

February 13, 2026
Iambic Therapeutics has entered a multi-year collaboration with Takeda to use its AI-driven platform for small molecule drug design in oncology and gastrointestinal research, with potential payments exceeding $1.7 billion.

Iambic Therapeutics has announced a multi-year collaboration with Takeda to apply its AI-driven discovery platform to small molecule drug design in Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas, announced in a press release.

The partnership will give Takeda access to Iambic’s NeuralPLexer model, which predicts protein-ligand complexes to accelerate drug discovery and development. Iambic will receive upfront, research cost, and technology access payments and could earn success-based payments exceeding $1.7 billion, along with royalties on any resulting products.

Iambic’s platform combines AI models with automated synthesis and experimental capabilities, enabling rapid design-make-test-analyze cycles. The collaboration aims to speed up the identification and optimization of small molecule drug candidates in high-priority therapeutic programs.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

02/13
OPAQUE Raises $24 Million Series B for Confidential AI Platform
02/13
Feedzai and Neterium Partner on Real-Time Financial Crime Screening
02/13
Robo.ai and DaBoss.AI Form UAE Joint Venture for Distributed Embodied AI Data Platform
02/13
Eve Security Files Patent for 'Interrogation-as-a-Service' to Manage AI Agent Risks
02/13
Kong Introduces Context Mesh to Connect Enterprise APIs with AI Agents

More from: Life Sciences

02/13
Robots & Pencils Releases AI-Focused Series on Healthcare Supply Chain Safety
02/11
Stellaromics Adds Stacie Weninger and Steve McPhail to Board of Directors
02/11
Accel-KKR Makes Strategic Investment in Exxat to Drive Healthcare Education Growth
02/11
Garner Health Raises $118 Million Series D Led by Kleiner Perkins
02/08
Brainomix Launches Next-Generation Stroke AI Platform with Net Water Uptake Feature

Subscribe to Enterprise AI Brief

Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.

AI Token Webinar

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more

You May Also Like